Oxaliplatin is one of the most commonly used drugs for patients with colorectal cancer. It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases. In all those instances, the patients had started receiving oxaliplatin, developed evidence of DIC during the course of planned treatment, and recovered with supportive care. We report a case of a 71-year-old man with colorectal cancer treated successfully with an oxaliplatin-based regimen who had disease relapse after 3 years. When treated again with oxaliplatin, he developed signs of an acute hypersensitivity reaction, and eventually had signs and symptoms consistent with DIC despite appropriate management. This case is unique in that a DIC reaction evolving from a hypersensitivity reaction occurred after the patient had already tolerated the drug years earlier. It suggests a possible immune-mediated etiology to this rare occurrence that should be kept in mind while utilizing this commonly employed drug.

Holch J, Stintzing S, Heinemann V: Treatment of metastatic colorectal cancer: standard of care and future perspectives. Visc Med 2016;32:178-183.
Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon cancer v2, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed 1 November 2015).
Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
Wong JT, Ling M, Patil S, Banerji A, Long A: Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014;2:40-45.
Garciaz S, Oziel-Taieb S, Dermeche S, Ries P, Vessaud J, Raoul JL: Acute immune hematological complication of oxaliplatin. A series of 3 cases. Tumori 2014;100:e17-e19.
Forcello NP, Khubchandani S, Patel SJ, Brahaj D: Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review. J Oncol Pharm Pract 2015;21:148-156.
Niu J, Mims MP: Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. J Clin Oncol 2012;30:e312-e314.
James E, Podoltsev N, Salehi E, Curtis BR, Saif MW: Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer 2009;8:220-224.
Kurian S, Macintyre J, Mushtaq M, Rocha-Lima CM, Ahn Y: Oxaliplatin-induced disseminated intravascular coagulation: a case report and review of literature. World J Gastrointest Oncol 2012;4:181-183.
Malkhasyan K, Halene S, Lacy J: Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer. Clin Colorectal Cancer 2015;14:e9-e12.
Meng L, Romano A, Smith E, Macik G, Grosh WW: Disseminated intravascular coagulation and immune hemolytic anemia, possibly Evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review. Clin Colorectal Cancer 2015;14:e1-e3.
Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G: Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001;86:828-833.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.